Document is current
Any future updates will be listed below
-
Authors
Rainey-Smith, Stephanie R.
Gu, Yian
Gardener, Samantha L.
Doecke, James D. https://orcid.org/0000-0003-2863-0293
Villemagne, Victor L.
Brown, Belinda M.
Taddei, Kevin
Laws, Simon M. https://orcid.org/0000-0002-4355-7082
Sohrabi, Hamid R. https://orcid.org/0000-0001-8017-8682
Weinborn, Michael
Ames, David
Fowler, Christopher
Macaulay, S. Lance https://orcid.org/0000-0001-5069-9516
Maruff, Paul
Masters, Colin L.
Salvado, Olivier
Rowe, Christopher C.
Scarmeas, Nikolaos
Martins, Ralph N.
- License Information
-
More Information
Article History
Received: 19 February 2018
Revised: 15 July 2018
Accepted: 24 July 2018
First Online: 30 October 2018
Conflict of interest
: V.L.V. served as a consultant for Bayer Pharma; and received research support from a NEDO grant from Japan. S.M.L. has previously been a paid consultant to Alzhyme. H.R.S. has received personal compensation for previous activities with Pfizer, and currently from Takeda Pharmaceuticals. D.A. has served on scientific advisory boards for Novartis, Eli Lilly, Janssen, and Pfizer Inc. P.M. is a full-time employee of Cogstate Ltd. C.L.M. is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. C.C.R. has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca; has received speaker honoraria from Bayer Pharma and GE Healthcare; and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. R.N.M. is founder of, and owns stock in, Alzhyme, and is a co-founder of the KaRa Institute of Neurological Diseases. S.R.R.S., Y.G., S.L.G., J.D.D., B.M.B., K.T., M.W., C.F., S.L.M., O.S. and N.S. report no disclosures.
